Comparar métodos

	Índice de Área y Severidad de la Psoriasis (PASI)	EASI (Índice de Área y Severidad del Eczema)	Índice SCORAD (SCORing Atopic Dermatitis)
Campo	Dermatología	Dermatología	Dermatología
Familia	Process / pipeline	Process / pipeline	Process / pipeline
Año de origen	1978	2001	1993
Autor original	Fredriksson T, Pettersson U	Hanifin JM, Thurston M	European Task Force on Atopic Dermatitis (ETFAD)
Tipo	Clinician-rated	Clinician-rated	Clinician-rated
Fuente seminal	Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157(4):238-244.	Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Experimental Dermatology. 2001;10(1):11-18.	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.
Alias	PASI Index	EASI Index	SCORAD Index
Relacionados	2	2	3
Resumen	The PASI is the gold-standard clinician-administered measure of psoriasis severity and extent. Developed by Fredriksson and Pettersson in 1978, it evaluates four cardinal clinical signs (erythema, induration, desquamation) across four body regions, each weighted by anatomical importance. PASI is the most widely used endpoint in psoriasis clinical trials and is endorsed by regulatory agencies (FDA, EMA) and international dermatology societies.	The EASI is a structured, clinician-administered tool for assessing the extent and intensity of atopic dermatitis across the body. Developed by Hanifin and colleagues in 2001, it divides the body into four regions with weighted area factors, ensuring proportional contribution to total score. EASI has become the primary objective severity measure in atopic dermatitis clinical trials and is recommended by international regulatory authorities (FDA, EMA).	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.